bat8001
mAbexperimentalADC
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Mar 7, 2017 (NCT04189211)
Timeline
Indications
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- maytansinoid
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04151329 | Phase 1/Phase 2 (Phase 2) | Jun 21, 2019 | Biothera |
| NCT04185649 | Phase 3 | Jul 1, 2018 | Biothera, Sun Yat-Sen University |
| NCT04189211 | Phase 1 | Mar 7, 2017 | Biothera, Sun Yat-Sen University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biothera | For profit | 3 | 3 | 3 | 2017 |
| Sun Yat-Sen University | Academic/Hospital | 2 | 0 | 2 | 2017 |
2 organizations
Page 1 / 1